Compare Digital Realty Trust, Inc. (DLR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Gilead Sciences, Inc. — how do they compare? Digital Realty Trust, Inc. trades at $176.85 (market cap $65.32B), while Gilead Sciences, Inc. trades at $148.65 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× Digital Realty Trust, Inc.'s market cap, and Digital Realty Trust, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Gilead Sciences, Inc. for 111 Days on average.
| DLR | GILD | |
|---|---|---|
Market Cap | $65.32B | $182.40B |
Volume | 2,563,950 | 4,469,821 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $155.80 |
52-Week Low | $147.93 | $116.74 |
Typical Hold Time | 94 Days | 111 Days |
Enterprise Value | $84.03B | $205.46B |
Dividend Yield | 2.77% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $180.47, down 2.26% today, with a bearish technical signal despite strong analyst support. The data center REIT shows robust revenue growth to $6.11B in 2025 and expanding AI infrastructure partnerships, though valuation metrics remain elevated with a P/E of 85.89. Recent earnings show mixed results with Q2 2026 beating expectations by 150%.
DLR presents a compelling AI infrastructure play with strong growth prospects but faces valuation concerns and execution risks. The consensus price target of $222.35 suggests 23% upside potential, supported by 69% analyst buy ratings. Key risks include high leverage and competitive pressures in the rapidly expanding data center market.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
